Differences in baseline characteristics between trials may also influence findings, as GLP-1 RAs were frequently studied in patients with atherosclerotic cardiovascular disease, whereas SGLT2 inhibitors showed greater efficacy in those with heart failure and chronic kidney disease. This evidence concerns the gene SLC5A2 and chronic kidney disease.